Anzor Pharmaceuticals Announces Groundbreaking Patent for Novel-Klotho Protein Therapy
Innovative Modified Soluble α-Klotho Protein Shows Promise for Treating the $16B Chronic Kidney Disease and Phosphate Metabolism Disord...
Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia XLH
The FDA Orphan Drug Designation provides significant advantages to investors by granting Anzor Pharmaceuticals valuable development inc...